VERAXA Biotech AG (NASDAQ: VRXA) announced today the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, who previously served as vice president of research and development, will now lead the advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart after a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development. Prior to joining VERAXA, he held leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development.
The appointment comes as VERAXA focuses on building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development, guided by rigorous quality-by-design principles. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research.
For more information, the full press release is available at https://nnw.fm/cR1RS. The latest news and updates relating to VRXA can be found in the company’s newsroom at https://ibn.fm/VRXA.
This leadership change signals VERAXA's commitment to accelerating its oncology pipeline. With Erkel's expertise in T-cell engagers and antibody engineering, the company aims to strengthen its position in the competitive immuno-oncology space. The BiTAC platform, which is central to VERAXA's strategy, represents a promising approach to targeting solid tumors, an area of high unmet medical need.
Investors and industry observers will be watching how Erkel's leadership influences the company's progress toward clinical milestones. The transition also underscores the importance of experienced leadership in navigating the complex landscape of cancer drug development.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings. Undue reliance should not be placed on these statements.
